Ayaz Madraswalla, MD
Addiction Medicine · Putnam, CTNPI 1902899859
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,250 of the $13,886 with a category attached, or 66.6%. Indivior Inc. accounts for 73.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $8,057 and has fallen 91.4% since, to $695 in 2025. Among addiction medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $66.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$10K
- AbbVie$456
- Boehringer Ingelheim$340
- Novo Nordisk$328
- Lilly USA, LLC$286
- AstraZeneca$268
- plus $2K from 34 others
What the payments were for
- Speaking & faculty fees$9,25067%
- Travel & lodging$1931%
- Food & beverage$4,44332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 28 | $10,248 |
| AbbVie(2 entities) | 23 | $456 |
| Boehringer Ingelheim | 15 | $340 |
| Novo Nordisk | 18 | $328 |
| Lilly USA, LLC | 15 | $286 |
| AstraZeneca | 17 | $268 |
| Merck | 12 | $188 |
| GSK | 9 | $171 |
| Eisai Inc. | 9 | $165 |
| Gilead | 2 | $145 |
| Pfizer | 7 | $124 |
| Amgen | 5 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Exact Sciences | 3 | $86 |
| Bayer | 4 | $75 |
| Amarin Pharma, Inc. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Sanofi | 1 | $36 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Genentech USA, Inc. | 2 | $34 |
| Dexcom, Inc. | 2 | $33 |
| Baxter Healthcare | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Novartis | 1 | $27 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| Scynexis, Inc. | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,886 in reported general payments places this provider in the 95th percentile of 28 addiction medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $87,194 |
| JardianceEmpagliflozin | 44 | $63,010 |
| EliquisApixaban | 53 | $45,254 |
| RybelsusSemaglutide | 11 | $29,941 |
| XareltoRivaroxaban | 13 | $22,120 |
| MounjaroTirzepatide | 17 | $20,408 |
| VraylarCariprazine Hcl | 12 | $17,077 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $14,271 |
| Spiriva HandihalerTiotropium Bromide | 12 | $10,233 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,263 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 16 | $4,936 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $4,276 |
| SynthroidLevothyroxine Sodium | 28 | $3,740 |
| Atorvastatin Calcium | 399 | $2,838 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $2,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $328 | $117,13581 claims |
| Boehringer IngelheimJardiance | $340 | $63,01044 claims |
| PfizerEliquis, Abrysvo | $124 | $50,19069 claims |
| Johnson & JohnsonXarelto | $15 | $22,12013 claims |
| AbbVieVraylar, Synthroid | $456 | $20,81740 claims |
| Lilly USA, LLCMounjaro | $286 | $20,40817 claims |
| MerckJanumet Xr | $188 | $14,27114 claims |
| GSKBreo Ellipta | $171 | $5,26313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 addiction medicine providers in Connecticut.
Other addiction medicine in Putnam
- Jenna ButnerNew Haven$27K
- Neal LakritzEnfield$3K
- Mahboob AslamRocky Hill$2K
- Thomas DefantiNorth Stonington$1K
- Edith HerganRocky Hill$1K
- John AntonucciNewington$1K
- Brian KarsifNew Haven$528
- Jay BensonRocky Hill$393
- Sijie WangFarmington$387
- Katherine GriecoHartford$376
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.